Jinan Carbotang Biotech Co., Ltd is a high-tech enterprise that specializing in the R&D, production and sales of pharmaceutical intermediates and fine chemicals, which was founded by Jinan Shengquan Group Share-holding Co.,Ltd and Carbosynth Limited UK in 2011. 

Keeping up with the industrial development trend, Carbotang can provide all-directional services that from laboratory-level molecular design, synthesis, supply to customized synthesis, process development and commercial production of the crucial intermediates. The company has over 1 000 square meters’ R&D laboratory and kilogram grade laboratories, and has built multi-functional cGMP workshop that meets the requirements of the EU; besides, the completion of the hydrogen workshop that further promotes the company’s production transformation capacity in CDMO market, which develops the “R&D--Production” system from laboratory, demo to large scale production. Carbotang has already passed authority certifications such as ISO9001, ISO14001, OHSAS18001 and etc, and the audit of many international pharmaceutical companies as well.

Carbotang has built its own pharmaceutical institute where with over 60 stuffs, and established close cooperation with many researchers from different institutes and universities such as: University of Oxford, Moscow State University, Latvia Institute of Organic Chemistry, Chinese Academy of Sciences, Fudan University, Beijing Institute of Technology and etc. Carbotang possesses its unique technical advantages wherein the field of synthesis, catalystic hydrogenation on the carbohydrate, nucleoside intermediates and their derivatives. Till now, the company has filed 52 patents with 41 granted, and succeeded in over 200 projects’ R&D, in which more than 100 projects had already been industrialized production.

Carbotang will always adhere to conduct its business ideology of "People-Oriented, Customer First", to win customers by its high professional techniques and good services, to cooperate with pharmaceutical companies foreign and domestic by diversified cooperation models, and to be the leader in edge pharmaceutical intermediates and API CDMO fields.